THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.: Dual Myeloid Disorder Treated with Two Drug Association. Mediterr J Hematol Infect Dis [Internet]. 2025 Feb. 27 [cited 2026 Jun. 10];17(1):e2025023. Available from: https://www.mjhid.org/mjhid/article/view/5901